Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABIO3419 is an intra-articular viscosupplementation gel developed by Abiogen Pharma for the treatment of knee osteoarthritis. The product consists of exogenous hyaluronic acid designed to replenish the diminished concentration and molecular weight of endogenous hyaluronan in the synovial fluid of osteoarthritic joints. By restoring the fluid's viscoelastic properties, ABIO3419 serves as a lubricant and shock absorber, thereby reducing joint pain and improving physical function. It has been evaluated in pivotal clinical trials to assess its safety and performance compared to standard treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ABIO3419.